Welcome to ZMB

The Center of Medical Biotechnology (ZMB) is an interdisciplinary scientific centre of the University of Duisburg-Essen, integrating medical research at the University Hospital and natural sciences at the Campus.

Introducing the ZMB

Watch our video to find out more about us.
Interviews were given by Shirley Knauer, Matthias Gunzer and Alexander Rösch.

By clicking this video will be loaded from Google YouTube. Their privacy policy applies.

Mit Nanopartikeln gegen multiresistente Keime

Kleiner, aber effizienter Trick

Sauer macht wirksam: Mit einem einfachen Trick könnten nanobasierte Antibiotika künftig effektiv gegen multiresistente Keime in Kliniken eingesetzt werden. Das haben Wissenschaftler der Universität Duisburg-Essen (UDE) kürzlich herausgefunden und ihre Ergebnisse nun in der Fachzeitschrift „Materials Today" veröffentlicht.

Prof. Shirley Knauer: „Wenn der pH-Wert in der Umgebungsmatrix angepasst wird, steigert dies die antibakterielle Effektivität der Nanopartikel entscheidend. Mit diesem einfachen Trick lösen wir die Wirkblockade, die durch angelagerte Proteine aus der Wundumgebung ausgelöst wurde.“

>> More
© freerangestock.com

Neues Medikament gegen altersbedingte Erblindung

Ziel in Sicht: therapeutischer Wirkstoff

[13.12.2018] Wenn Buchstaben oder Gesichter nur noch verschwommen oder verzerrt gesehen werden, kann dies mit der altersbedingten Makuladegeneration (AMD) zu tun haben. Neue Wirkstoffe, um die hierzulande mit Abstand häufigste Erblindungsursache behandeln zu können, entwickelt ein neues Forschungsprojekt der Universität Duisburg-Essen (UDE) zusammen mit der Lead Discovery Center GmbH (LDC).

Möglich wird dies durch den Leitmarktwettbewerb LifeSciences.NRW, der das Dreijahres-Vorhaben mit 905.000 Euro unterstützt. Das gesamte Projektvolumen beträgt 1,3 Millionen Euro.

more aboutZiel in Sicht: therapeutischer Wirkstoff

© Gunzer

DFG fördert modernste Technologie

Lichtblattmikroskop

[12.12.2018] Ein Lichtblattmikroskop der neuesten Bauart wird ab 2019 der Medizinischen Fakultät der Universität Duisburg-Essen (UDE) zur Verfügung stehen. Prof. Dr. Matthias Gunzer, Direktor des Instituts für experimentelle Immunologie und Bildgebung, konnte dafür rund 690.000 Euro bei der Deutschen Forschungsgemeinschaft (DFG) einwerben.

„Damit wird es nun am Universitätsklinikum Essen möglich sein, menschliches oder tierisches Gewebe in nie dagewesener Qualität dreidimensional sichtbar zu machen“, so Prof. Gunzer. Durch verbesserte optische Eigenschaften und neue Auswertealgorithmen können auch feinste Details in den Bildern sichtbar gemacht werden.

more aboutLichtblattmikroskop

© Tanyajoy – stock.adobe.com

Rausch der Hormone

Jede Zelle unseres Körpers ist glücklich...

[13.12.2018] Liebe beginnt im Gehirn. Dort wird ein biochemischer Cocktail gemixt, der uns bis zu den Zehen flasht.

Ob wir verknallt sind oder der Sturm der Gefühle später einer tiefen Verbundenheit weicht: Regisseure der Liebe sind die Hormone. Sie spielen mit anderen Boten- und Signalstoffen zusammen und entstehen im Kopf. In diesem setzen Schaltkreise wie beispielsweise das Belohnungszentrum eine Reihe von Prozessen in Gang.

„Was im Körper passiert, wenn wir lieben, ist ein so komplexer Prozess. Er gibt der Wissenschaft noch viele Rätsel auf“, schickt Professorin Dr. Dagmar Führer-Sakel vorweg. Bekannt ist: Die biochemischen Abläufe bei Männern und Frauen sind nicht gleich; außerdem rauscht je nach Stadium der Beziehung ein anderer Hormoncocktail durch die Blutbahn, und es sind verschiedene Hirnareale beteiligt.

>> More

1st European Symposium on Myeloid Regulatory Cells in Health and Disease

The first European Symposium on Myeloid Regulatory Cells in Health and Disease took place on November 1–3, 2018 at the University Hospital Essen. 160 renowned scientists from 23 countries came together to present and to discuss the most recent developments in the field and to improve the international exchange. The clear focus of the conference allowed to dicuss specific properties of the myeloid regulatory cells in a European conference for the first time, which was very much appreciated by all participants. The conference was chaired by ZMB member Prof. Dr. Sven Brandau, head of the research division of the Department of Otorhinolaryngology at the University Hospital Essen.
Myeloid cells with regulatory function (e.g. myeloid suppressor cells, regulatory macrophages, or tolerogenic DC) have been shown to be detrimental in infections, inflammation and cancer, but have become a promising therapeutic tool to treat autoimmune diseases, severe allergies, or to improve transplantation outcomes.
Please find the post conference report (German only) by downloading this PDF.

Recent Publications

2018

Grob JJ, Garbe C, Ascierto P, Larkin J, Dummer R, Schadendorf D. Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma? Lancet Oncol. 2018 Dec;19(12):e720-e725. Review.

Siemer S, Westmeier D, Vallet C, Becker S, Voskuhl J, Ding GB, Thines E, Stauber RH, Knauer SK. Resistance to Nano-Based Antifungals Is Mediated by Biomolecule Coronas. ACS Appl Mater Interfaces. 2018 Dec 18.[Epub ahead of print].

Juric D, Janku F, Rodón J, Burris HA, Mayer IA, Schuler M, Seggewiss-Bernhardt R, Gil-Martin M, Middleton MR, Baselga J, Bootle D, Demanse D, Blumenstein L, Schumacher K, Huang A, Quadt C, Rugo HS. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial. JAMA Oncol. 2018 Dec 13:e184475.  [Epub ahead of print].

Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, Bartenhagen C, Walter E, Gecht J, Kerschke L, Volland R, Menon R, Heuckmann JM, Gartlgruber M, Hartlieb S, Henrich KO, Okonechnikov K, Altmüller J, Nürnberg P, Lefever S, de Wilde B, Sand F, Ikram F, Rosswog C, Fischer J, Theissen J, Hertwig F, Singhi AD, Simon T, Vogel W, Perner S, Krug B, Schmidt M, Rahmann S, Achter V, Lang U, Vokuhl C, Ortmann M, Büttner R, Eggert A, Speleman F, O'Sullivan RJ, Thomas RK, Berthold F, Vandesompele J, Schramm A, Westermann F, Schulte JH, Peifer M, Fischer M. A mechanistic classification of clinical phenotypes in neuroblastoma. Science. 2018 Dec 7;362(6419):1165-1170.

Siemer S, Westmeier D, Barz M, Eckrich J, Wünsch D, Seckert C, Thyssen C, Schilling O, Hasenberg M, Pang C, Docter D, Knauer SK, Stauber RH, Strieth S. Biomolecule-corona formation confers resistance of bacteria to nanoparticle-induced killing: Implications for the design of improved nanoantibiotics. Biomaterials. 2018 Nov 21;192:551-559. [Epub ahead of print].

Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C, Goff M, Love SB, Mohammed SB, Middleton MR. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Ann Oncol. 2018 Nov 14. [Epub ahead of print].

Jerby-Arnon L, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 Nov 1;175(4):984-997.e24. 

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2018 Oct 25. [Epub ahead of print].

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Nov;19(11):1480-1492. Epub 2018 Oct 22. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668. Lancet Oncol. 2018 Nov;19(11):e581.

Urbonas V, Schadendorf D, Zimmer L, Danson S, Marshall E, Corrie P, Wheater M, Plummer E, Mauch C, Scudder C, Goff M, Love SB, Mohammed SB, Middleton MR. Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Ann Oncol. 2018 Nov 14. [Epub ahead of print].

Casanova-Acebes M, Nicolás-Ávila JA, Li JL, García-Silva S, Balachander A, Rubio-Ponce A, Weiss LA, Adrover JM, Burrows K, A-González N, Ballesteros I, Devi S, Quintana JA, Crainiciuc G, Leiva M, Gunzer M, Weber C, Nagasawa T, Soehnlein O, Merad M, Mortha A, Ng LG, Peinado H, Hidalgo A. Neutrophils instruct homeostatic and pathological states in naive tissues. J Exp Med. 2018 Nov 5;215(11):2778-2795.

Totzeck M, Mahabadi AA, Schlosser T, Rassaf T. Weightlifting unmasks high-risk coronary anomaly. Eur Heart J. 2018 Nov 13. [Epub ahead of print].

Jockenhöfer F, Schimming TT, Schaller J, Moege J, Livingstone E, Salva KA, Zimmer L, Schadendorf D, Rösch A. Sebaceous tumours: more than skin deep. Gut. 2018 Nov;67(11):1957.

Jerby-Arnon L, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 Nov 1;175(4):984-997.e24.

Weith M, Seiler J, van den Boom J, Kracht M, Hülsmann J, Primorac I, del Pino Garcia J, Kaschani F, Kaiser M, Musacchio A, Bollen M, Meyer H. Ubiquitin-independent disassembly by a p97 AAA-ATPase complex drives PP1 holoenzyme formation. Mol Cell, 2018, doi: 10.1016/j.molcel.2018.09.020.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. JAMA Oncol. 2018 Oct 25. [Epub ahead of print].

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Haas T, Shilkrut M, Gasal E, Kefford R, Kirkwood JM, Long GV. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 Oct 22:JCO1801219.

Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Oct 18. pii: S1470-2045(18)30700-9.

Knier B, Hiltensperger M, Sie C, Aly L, Lepennetier G, Engleitner T, Garg G, Muschaweckh A, Mitsdörffer M, Koedel U, Höchst B, Knolle P, Gunzer M, Hemmer B, Rad R, Merkler D, Korn T. Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity. Nat Immunol. 2018 Oct 29.[Epub ahead of print].

Wagener R, López C, Kleinheinz K, Bausinger J, Aukema SM, Nagel I, Toprak UH, Seufert J, Altmüller J, Thiele H, Schneider C, Kolarova J, Park J, Hübschmann D, Murga Penas EM, Drexler HG, Attarbaschi A, Hovland R, Kjeldsen E, Kneba M, Kontny U, de Leval L, Nürnberg P, Oschlies I, Oscier D, Schlegelberger B, Stilgenbauer S, Wössmann W, Schlesner M, Burkhardt B, Klapper W, Jaffe ES, Küppers R, Siebert R. IG-MYC-positive neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas. Blood. 2018 Oct 3. pii: blood-2018-03-842088.

Lang S, Bruderek K, Kaspar C, Höing B, Kanaan O, Dominas N, Hussain T, Droege F, Eyth C, Hadaschik B, Brandau S. Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets. Clin Cancer Res. 2018 Oct 1;24(19):4834-4844.

Mangolini M, Götte F, Moore A, Ammon T, Oelsner M, Lutzny-Geier G, Klein-Hitpass L, Williamson JC, Lehner PJ, Dürig J, Möllmann M, Rásó-Barnett L, Hughes K, Santoro A, Méndez-Ferrer S, Oostendorp RAJ, Zimber-Strobl U, Peschel C, Hodson DJ, Schmidt-Supprian M, Ringshausen I. Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia. Nat Commun. 2018 Sep 21;9(1):3839.

Pesenti ME, Prumbaum D, Auckland P, Smith CM, Faesen AC, Petrovic A, Erent M, Maffini S, Pentakota S, Weir JR, Lin YC, Raunser S, McAinsh AD, Musacchio A. Reconstitution of a 26-Subunit Human Kinetochore Reveals Cooperative Microtubule Binding by CENP-OPQUR and NDC80. Mol Cell. 2018 Sep 20;71(6):923-939.e10.

Dührsen U, Müller S, Rekowski J, Hüttmann A. Reply to H.J.A Adams et al and C.Gisselbrecht. J Clin Oncol. 2018 Sep 17:JCO1800898.

Schadendorf D, Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S. Lancet Seminar – Melanoma. The Lancet, 2018 Sep 15;392(10151):971-984. Review.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 Sep 12. pii: S1470-2045(18)30497-2.

Mahabadi AA, Rassaf T. Imaging of coronary inflammation for cardiovascular risk prediction. Lancet. 2018 Aug 24. pii: S0140-6736(18)31716-1. [Epub ahead of print].

Miao et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 Sep;50(9):1271-1281.

Kurtz DM, et al. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018 Aug 20:JCO2018785246.

Horsthemke B. A critical view on transgenerational epigenetic inheritance in humans. Nat Commun. 2018 Jul 30;9(1):2973.

Horst AK, Wegscheid C, Schaefers C, Schiller B, Neumann K, Lunemann S, Langeneckert AE, Oldhafer KJ, Weiler-Normann C, Lang KS, Singer BB, Altfeld M, Diehl L, Tiegs G. Carcinoembryonic antigen-related cell adhesion molecule 1 controls IL-2-dependent regulatory T-cell induction in immune-mediated hepatitis in mice.Hepatology. 2018 Jul;68(1):200-214.

Westmeier D, Solouk-Saran D, Vallet C, Siemer S, Docter D, Götz H, Männ L, Hasenberg A, Hahlbrock A, Erler K, Reinhardt C, Schilling O, Becker S, Gunzer M, Hasenberg M, Knauer SK, Stauber RH. Nanoparticle decoration impacts airborne fungal pathobiology. Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):7087-7092.

Khairnar V, Duhan V, Patil AM, Zhou F, Bhat H, Thoens C, Sharma P, Adomati T, Friendrich SK, Bezgovsek J, Dreesen JD, Wennemuth G, Westendorf AM, Zelinskyy G, Dittmer U, Hardt C, Timm J, Göthert JR, Lang PA, Singer BB, Lang KS. CEACAM1 promotes CD8(+) T cell responses and improves control of a chronic viral infection. Nat Commun. 2018 Jul 2;9(1):2561.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Dührsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H; German-speaking Myeloma Multicenter Group (GMMG). Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia. 2018 Jun 29.[Epub ahead of print].

Trusch F, Loebach L, Wawra S, Durward E, Wuensch A, Iberahim NA, de Bruijn I, MacKenzie K, Willems A, Toloczko A, Diéguez-Uribeondo J, Rasmussen T, Schrader T, Bayer P, Secombes CJ, van West P. Cell entry of a host-targeting protein of oomycetes requires gp96. Nat Commun. 2018 Jun 14;9(1):2347.

Weske S, Vaidya M, Reese A, von Wnuck Lipinski K, Keul P, Bayer JK, Fischer JW, Flögel U, Nelsen J, Epple M, Scatena M, Schwedhelm E, Dörr M, Völzke H, Moritz E, Hannemann A, Rauch BH, Gräler MH, Heusch G, Levkau B. Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat Med. 2018 May;24(5):667-678.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603-615.

Ter Veer E, et al. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol. 2018 Mar;19(3):e151-e160. Review.

Ziemann S, van der Linde K, Lahrmann U, Acar B, Kaschani F, Colby T, Kaiser M, Ding Y, Schmelz E, Huffaker A, Holton N, Zipfel C, Doehlemann G. An apoplastic peptide activates salicylic acid signalling in maize. Nat Plants. 2018 Mar;4(3):172-180.

Maio M, Lewis K, Demidov L, Mandalà M, Bondarenko I, Ascierto PA, Herbert C, Mackiewicz A, Rutkowski P, Guminski A, Goodman GR, Simmons B, Ye C, Yan Y, Schadendorf D; BRIM8 Investigators. Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):510-520.

McQuade JL, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 Mar;19(3):310-322.

Tucci FA, Kitanovski S, Johansson P, Klein-Hitpass L, Kahraman A, Dürig J, Hoffmann D, Küppers R. Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals. Blood. 2018 Feb 1;131(5):546-557.

Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JHM, Middleton MR, Berlin J, Schuler M, Gil-Martin M, Rugo HS, Seggewiss-Bernhardt R, Huang A, Bootle D, Demanse D, Blumenstein L, Coughlin C, Quadt C, Baselga J. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. J Clin Oncol. 2018 Feb 5:JCO2017727107.

Pöhler R, Krahn JH, van den Boom J, Dobrynin G, Kaschani F, Eggenweiler HM, Zenke FT, Kaiser M, Meyer H. A Non-Competitive Inhibitor of VCP/p97 and VPS4 Reveals Conserved Allosteric Circuits in Type I and II AAA ATPases. Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1576-1580.

Ross B, Krapp S, Augustin M, Kierfersauer R, Arciniega M, Geiss-Friedlander R, Huber R. Structures and mechanism of dipeptidyl peptidases 8 and 9, important players in cellular homeostasis and cancer. Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1437-E1445.

Schadendorf D, Jiang J, Kelleher T, Postow MA. Reply to M. Horiguchi et al. J Clin Oncol. 2018 Mar 1;36(7):721.

Tucci FA, Kitanovski S, Johansson P, Klein-Hitpass L, Kahraman A, Dürig J, Hoffmann D, Küppers R. Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals. Blood. 2018 Feb 1;131(5):546-557.

Pöhler R, Krahn JH, van den Boom J, Dobrynin G, Kaschani F, Eggenweiler HM,Zenke FT, Kaiser M, Meyer H. A non-competitive inhibitor of VCP/p97 and VPS4 reveals conserved allosteric circuits in type I and II AAA ATPases. Angew Chem Int Ed Engl. 2018 Feb 5;57(6):1576-1580.

van den Boom J, Meyer H. VCP/p97-Mediated Unfolding as a Principle in Protein Homeostasis and Signaling. Mol Cell. 2018 Jan 18;69(2):182-194. Review.

↑2018 top

Hönes GS, Rakov H, Logan J, Liao XH, Werbenko E, Pollard AS, Præstholm SM, Siersbæk MS, Rijntjes E, Gassen J, Latteyer S, Engels K, Strucksberg KH, Kleinbongard P, Zwanziger D, Rozman J, Gailus-Durner V, Fuchs H, Hrabe de Angelis M, Klein-Hitpass L, Köhrle J, Armstrong DL, Grøntved L, Bassett JHD, Williams GR, Refetoff S, Führer D, Moeller LC. Noncanonical thyroid hormone signaling mediates cardiometabolic effects in vivo. Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11323-E11332.

von Wnuck Lipinski K, Weske S, Keul P, Peters S, Baba HA, Heusch G, Gräler MH, Levkau B. Hepatocyte nuclear factor 1A deficiency causes hemolytic anemia in mice by altering erythrocyte sphingolipid homeostasis. Blood. 2017 Dec 21;130(25):2786-2798.

Sokolova V, Shi Z, Huang S, Du Y, Kopp M, Frede A, Knuschke T, Buer J, Yang D, Wu J, Westendorf AM, Epple M. Delivery of the TLR ligand poly(I:C) to liver cells in vitro and in vivo by calcium phosphate nanoparticles leads to a pronounced immunostimulation. Acta Biomater. 2017 Dec;64:401-410.

Graessl M, Koch J, Calderon A, Kamps D, Banerjee S, Mazel T, Schulze N, Jungkurth JK, Patwardhan R, Solouk D, Hampe N, Hoffmann B, Dehmelt L, Nalbant P. An excitable Rho GTPase signaling network generates dynamic subcellular contraction patterns. J Cell Biol. 2017 Dec 4;216(12):4271-4285.

Romagnani A, Vettore V, Rezzonico-Jost T, Hampe S, Rottoli E, Nadolni W, Perotti M, Meier MA, Hermanns C, Geiger S, Wennemuth G, Recordati C, Matsushita M, Muehlich S, Proietti M, Chubanov V, Gudermann T, Grassi F, Zierler S. TRPM7 kinase activity is essential for T cell colonization and alloreactivity in the gut. Nat Commun. 2017 Dec 4;8(1):1917.

Gunzer M. Escaping the traps of your own hunters. Science. 2017 Dec 1;358(6367):1126-1127.

Schadendorf D et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol. 2017 Dec 1;35(34):3807-3814.

Schmitzberger F*, Richter MM, Gordiyenko Y, Robinson CV, Dadlez M, Westermann S. Molecular basis for inner kinetochore configuration through RWD domain–peptide interactions. The EMBO Journal (2017) Dec 1;36(23):3458-3482. * corresponding author

Krzywinska E, Kantari-Mimoun C, Kerdiles Y, Sobecki M, Isagawa T, Gotthardt D, Castells M, Haubold J, Millien C, Viel T, Tavitian B, Takeda N, Fandrey J, Vivier E, Sexl V, Stockmann C. Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis. Nat Commun. 2017 Nov 17;8(1):1597.

Schmuck C, Jiang H, Hu XY, Schlesiger S, Li M, Zellermann E, Knauer S. Morphology Dependent Cell Imaging by a Self-assembled Diacetylene Peptide Amphiphile. Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14526-14530.

Hogeweg A, Sowislok A, Schrader T, Beuck C. An NMR Method To Pinpoint Supramolecular Ligand Binding to Basic Residues on Proteins. Angew Chem Int Ed Engl. 2017 Nov 13;56(46):14758-14762.

Long GV, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 Nov 9;377(19):1813-1823.

van der Vaart B, Fischböck J, Mieck C, Pichler P, Mechtler K, Medema RH, Westermann S. TORC1 signaling exerts spatial control over microtubule dynamics by promoting nuclear export of Stu2. J Cell Biol. 2017 Nov 6;216(11):3471-3484.

Long GV, Weber JS, Larkin J, Atkinson V, Grob JJ, Schadendorf D, Dummer R, Robert C, Márquez-Rodas I, McNeil C, Schmidt H, Briscoe K, Baurain JF, Hodi FS, Wolchok JD. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncol. 2017 Nov 1;3(11):1511-1519.

Herold S, Sockel K, Sayehli C, Herbst R, Dührsen U, Oelschlägel U, Böttner A,Hindahl H, Kullmer J, Helas S, Sauer M, Mohr B, Mies A, Bornhäuser M, Ehninger G, Röllig C, Thiede C, Platzbecker U. Evolution of NPM1-negative therapy-relatedmyelodysplastic syndromes following curative treatment of NPM1-mutant AML. Leukemia. 2017 Oct;31(10):2247-2251.

Wang J, Hossain M, Thanabalasuriar A, Gunzer M, Meininger C, Kubes P. Visualizing the function and fate of neutrophils in sterile injury and repair. Science. 2017 Oct 6;358(6359):111-116.

Wolchok JD, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2017 Oct 5;377(14):1345-1356.

Jacquelot N, et.al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017 Sep 19;8(1):592.

Item F, Wueest S, Lemos V, Stein S, Lucchini FC, Denzler R, Fisser MC, Challa TD, Pirinen E, Kim Y, Hemmi S, Gulbins E, Gross A, O'Reilly LA, Stoffel M, Auwerx J, Konrad D. Fas cell surface death receptor controls hepatic lipid metabolism by regulating mitochondrial function. Nat Commun. 2017 Sep 7;8(1):480.

Ahci M, Toffalori C, Bouwmans E, Crivello P, Brambati C, Pultrone C, Stempelmann K, Bost D, Mazzi B, Beelen DW, Ciceri F, Mulder W, Fleischhauer K, Vago L. A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT. Blood. 2017 Sep 7;130(10):1270-1273.

Tsegaw YA, Kadam PE, Tötsch N, Sanchez-Garcia E, Sander W. Is Magnetic Bistability of Carbenes a General Phenomenon? Isolation of Simple Aryl(trifluoromethyl)carbenes in Both Their Singlet and Triplet States. J Am Chem Soc. 2017 Sep 6;139(35):12310-12316.

Duncan L, Yilmaz Z, Gaspar H, Walters R, Goldstein J, Anttila V, Bulik-Sullivan B, Ripke S; Eating Disorders Working Group of the Psychiatric Genomics Consortium, Thornton L, Hinney A, Daly M, Sullivan PF, Zeggini E, Breen G, Bulik CM. Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. Am J Psychiatry. Sep 1;174(9):850-858.

Fleischhauer K, Shaw BE. HLA-DP in unrelated hematopoietic cell transplantation revisited: challenges and opportunities. Blood. 2017 Aug 31;130(9):1089-1096.

Zocchi D, Wennemuth G, Oka Y. The cellular mechanism for water detection in the mammalian taste system. Nat Neurosci. 2017 Jul;20(7):927-933.

Köcher S, Rey J, Bongard J, Tiaden AN, Meltzer M, Richards PJ, Ehrmann M, Kaiser M. Tailored Ahp-cyclodepsipeptides as Potent Non-covalent Serine Protease Inhibitors. Angew Chem Int Ed Engl. 2017 Jul 10;56(29):8555-8558.

van der Meer SB, Knuschke T, Frede A, Schulze N, Westendorf AM, Epple M. Avidin-conjugated calcium phosphate nanoparticles as a modular targeting system for the attachment of biotinylated molecules in vitro and in vivo. Acta Biomater. 2017 Jul 15;57:414-425.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R,Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M,Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. J Clin Oncol. 2017 Jul 3:JCO2016718023.

Lollies A, Hartmann S, Schneider M, Bracht T, Weiß AL, Arnolds J, Klein-Hitpass L, Sitek B, Hansmann ML, Küppers R, Weniger MA. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma. Leukemia. 2017 Jun 29. [Epub ahead of print]

Jana P, Samanta K, Bäcker S, Zellermann E, Knauer S, Schmuck C. Efficient Gene Transfection through Inhibition of β-Sheet (Amyloid Fiber) Formation of a Short Amphiphilic Peptide by Gold Nanoparticles. Angew Chem Int Ed Engl. 2017, 56, 8083.

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf AM, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank KG, Paschen A. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017 May 31;8:15440.

Ascierto PA, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol.2017 May;18(5):611-622.

Zweerink S, Kallnik V, Ninck S,Nickel S, Verheyen J, Blum M, Wagner A, Feldmann I, Sickmann A, Albers SV, Bräsen C, Kaschani F, Siebers B & Kaiser M. Activity-based protein profiling as a robust method for enzyme identification and screening in extremophilic Archaea. Nat Commun. 2017/05/08/online.

Vöpel T, Bravo-Rodriguez K, Mittal S, Vachharajani S, Gnutt D, Sharma A, Steinhof A, Fatoba O, Ellrichmann G, Nshanian M, Heid C, Loo JA, Klärner FG, Schrader T, Bitan G, Wanker EE, Ebbinghaus S, Sanchez-Garcia E. Inhibition of Huntingtin Exon-1 Aggregation by the Molecular Tweezer CLR01. J Am Chem Soc 2017 Apr 26;139(16):5640-5643.

Klein JC, Moses K, Zelinskyy G, Sody S, Buer J, Lang S, Helfrich I, Dittmer U, Kirschning CJ, Brandau S. Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun. 2017 Mar 16;8:14600.

Brandau S, Hartl D. Lost in neutrophil heterogeneity? CD10! Blood. 2017 Mar 9;129(10):1240-1241.

Kalkavan H, Sharma P, Kasper S, Helfrich I, Pandyra AA, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle PA, Wollmann G, von Laer D, Drexler I, Rathbun J, Cannon PM, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang PA, Lang KS. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. Nat Commun. 2017 Mar 1;8:14447.

Heid I, Steiger K, Trajkovic-Arsic M, Settles M, Eßwein MR, Erkan M, Kleeff J, Jäger C, Friess H, Haller B, Steingötter A, Schmid RM, Schwaiger M, Rummeny EJ, Esposito I, Siveke JT, Braren RF. Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer. Clin Cancer Res. 2017 Mar 15;23(6):1461-1470.

Dréno B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, Grob JJ, Puig S, Gilberg F, Bergström D, Page DR, Rogers G, Schadendorf D. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):404-412.

Sprengel A, Lill P, Stegemann P, Bravo-Rodriguez K, Schöneweiß EC, Merdanovic M, Gudnason D, Aznauryan M, Gamrad L, Barcikowski S, Sanchez-Garcia E, Birkedal V, Gatsogiannis C, Ehrmann M, Saccà B. Tailored protein encapsulation into a DNA host using geometrically organized supramolecular interactions. Nat Commun. 2017 Feb 16;8:14472.

Wang-Gillam A, Von Hoff D, Siveke J, Hubner R, Belanger B, Pipas JM, Chen LT. Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. J Clin Oncol. 2017 Feb 20;35(6):689-690.

Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med. 2017 Feb 9;376(6):536-547.

Faesen AC, Thanasoula M, Maffini S, Breit C, Müller F, van Gerwen S, Bange T, Musacchio A. Basis of catalytic assembly of the mitotic checkpoint complex. Nature. 2017 23;542(7642):498-502.

Papadopoulos C, Kirchner P, Bug M, Grum D, Koerver L, Schulze N, Poehler R, Dressler A, Fengler S, Arhzaouy K, Lux V, Ehrmann M, Weihl CC, Meyer H. VCP/p97 cooperates with YOD1, UBXD1 and PLAA to drive clearance of ruptured lysosomes by autophagy. EMBO J. 2017 Jan 17;36(2):135-150.

Nogova L, Sequist LV, Perez Garcia JM, Andre F, Delord JP, Hidalgo M, Schellens JH, Cassier PA, Camidge DR, Schuler M, Vaishampayan U, Burris H, Tian GG, Campone M, Wainberg ZA, Lim WT, LoRusso P, Shapiro GI, Parker K, Chen X, Choudhury S, Ringeisen F, Graus-Porta D, Porter D, Isaacs R, Buettner R, Wolf J. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. J Clin Oncol. 2017 Jan 10;35(2):157-165.

Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG. Inactivation of Capicua drives cancer metastasis. Nat Genet. 2017 Jan;49(1):87-96.

↑2017 top

Petrovic A, Keller J, Liu Y, Overlack K, John J, Dimitrova YN, Jenni S, van Gerwen S, Stege P, Wohlgemuth S, Rombaut P, Herzog F, Harrison SC, Vetter IR, Musacchio A. Structure of the MIS12 Complex and Molecular Basis of Its Interaction with CENP-C at Human Kinetochores. Cell. 2016 Nov 3;167(4):1028-1040.e15.

Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 2016 Nov 15. pii: S1470-2045(16)30578-2.

Jana P, Ehlers M, Zellermann E, Samanta K, Schmuck C. pH-Controlled Formation of a Stable β-Sheet and Amyloid-like Fibers from an Amphiphilic Peptide: The Importance of a Tailor-Made Binding Motif for Secondary Structure Formation. Angew Chem Int Ed Engl 2016 Dec 5;55(49):15287-15291.

Hu Y, Kim JH, He K, Wan Q, Kim J, Flach M, Kirchhausen T, Vortkamp A, Winau F. Scramblase TMEM16F terminates T cell receptor signaling to restrict T cell exhaustion. J Exp Med. 2016 Nov 14;213(12):2759-2772.

Merino F, Raunser S. Cryo-EM as a tool for structure-based drug development. Angew Chem Int Ed Engl. 2016 Nov 10. [Epub ahead of print].

Arumughan A, Roske Y, Barth C, Forero LL, Bravo-Rodriguez K, Redel A, Kostova S, McShane E, Opitz R, Faelber K, Rau K, Mielke T, Daumke O, Selbach M, Sanchez-Garcia E, Rocks O, Panáková D, Heinemann U, Wanker EE. Quantitative interaction mapping reveals an extended UBX domain in ASPL that disrupts functional p97 hexamers. Nat Commun. 2016 Oct 20;7:13047.

Javaheri A, Kruse T, Moonens K, Mejías-Luque R, Debraekeleer A, Asche CI, Tegtmeyer N, Kalali B, Bach NC, Sieber SA, Hill DJ, Königer V, Hauck CR, Moskalenko R, Haas R, Busch DH, Klaile E, Slevogt H, Schmidt A, Backert S, Remaut H, Singer BB, Gerhard M. Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nat Microbiol. 2016 Oct 17;2:16189.

Molodtsov MI, Mieck C, Dobbelaere J, Dammermann A, Westermann S*, Vaziri A*. A Force-Induced Directional Switch of a Molecular Motor Enables Parallel Microtubule Bundle Formation. Cell. 2016 Oct 6;167(2):539-552.e14, *co-corresponding authors.

Knorr J, Sokkar P, Schott S, Costa P, Thiel W, Sander W, Sanchez-Garcia E,Nuernberger P. Competitive solvent-molecule interactions govern primary processes of diphenylcarbene in solvent mixtures. Nat Commun. 2016 Oct 6;7:12968.

van den Boom J, Wolf M, Weimann L, Schulze N, Li F, Kaschani F, Riemer A, Zierhut C, Kaiser M, Iliakis G, Funabiki H, Meyer H. VCP/p97 extracts sterically trapped Ku70/80 rings from DNA in double strand break repair. Mol. Cell, 2016, 64: 189–198.

Gatsogiannis C, Merino F, Prumbaum D, Roderer D, Leidreiter F, Meusch D, Raunser S. Membrane insertion of a Tc toxin in near-atomic detail. Nat Struct Mol Biol. 2016 Oct;23(10):884-890.

Al-Batran SE et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016 Oct 21. pii: S1470-2045(16)30531-9.

Lu LL, Chung AW, Rosebrock TR, Ghebremichael M, Yu WH, Grace PS, Schoen MK, Tafesse F, Martin C, Leung V, Mahan AE, Sips M, Kumar MP, Tedesco J, Robinson H, Tkachenko E, Draghi M, Freedberg KJ, Streeck H, Suscovich TJ, Lauffenburger DA, Restrepo BI, Day C, Fortune SM, Alter G. A Functional Role for Antibodies in Tuberculosis. Cell. Cell 2016 Oct 6;167(2):433-443.e14.

Dahms SO, Arciniega M, Steinmetzer T, Huber R, Than ME. Structure of the unliganded form of the proprotein convertase furin suggests activation by a substrate-induced mechanism. Proc Natl Acad Sci U S A2016 Oct 4;113(40):11196-11201.

Li M, Radić Stojković M, Ehlers M, Zellermann E, Piantanida I, Schmuck C. Use of an Octapeptide-Guanidiniocarbonylpyrrole Conjugate for the Formation of a Supramolecular β-Helix that Self-Assembles into pH-Responsive Fibers. Angew Chem Int Ed Engl. 2016 Oct 10;55(42):13015-13018.

Pekgöz Altunkaya G, Malvezzi F, Demianova Z, Zimniak T, Litos G, Weissmann F, Mechtler K, Herzog F, Westermann S. CCAN Assembly Configures Composite Binding Interfaces to Promote Cross-Linking of Ndc80 Complexes at the Kinetochore. Curr Biol. 2016 Sep 12;26(17):2370-8.

Buiting K, Williams C, Horsthemke B. Angelman syndrome - insights into a rare neurogenetic disorder. Nat Rev Neurol. 2016 Oct;12(10):584-93. Review.

Hauschild A, Schadendorf D. Checkpoint inhibitors: a new standard of care for advanced Merkel cell carcinoma? Lancet Oncol. 2016 Sep 1. pii: S1470-2045(16)30441-7.

Weir JR, Faesen AC, Klare K, Petrovic A, Basilico F, Fischböck J, Pentakota S, Keller J, Pesenti ME, Pan D, Vogt D, Wohlgemuth S, Herzog F, Musacchio A. Insights from biochemical reconstitution into the architecture of human kinetochores. Nature. 2016 Aug 31;537(7619):249-253.

Carapito R,et al. Matching for the non-conventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. Blood. 2016 Aug 22. pii: blood-2016-05-719070.

Seifert M, Küppers R. Human memory B cells. Leukemia. 2016 Aug 26. doi: 10.1038/leu.2016.226. Review.

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW and Hentsch B. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study J Hepatol 65: 280-288, 2016.

Streich C, Akkari L, Decker C, Bormann J, Rehbock C, Müller-Schiffmann A, Niemeyer FC, Nagel-Steger L, Willbold D, Sacca B, Korth C, Schrader T, Barcikowski S. Characterizing the Effect of Multivalent Conjugates Composed of Aβ-Specific Ligands and Metal Nanoparticles on Neurotoxic Fibrillar Aggregation. ACS Nano. 2016 Aug 23; 10(8): 7582-97.

Klingberg A, Hasenberg A, Ludwig-Portugall I, Medyukhina A, Männ L, Brenzel A, Engel DR, Figge MT, Kurts C, Gunzer M. Fully Automated Evaluation of Total Glomerular Number and Capillary Tuft Size in Nephritic Kidneys Using Lightsheet Microscopy. J Am Soc Nephrol. 2016 Aug 3. pii: ASN.2016020232.

Männ L, Kochupurakkal N, Martin C, Verjans E, Klingberg A, Sody S, Kraus A, Dalimot J, Bergmüller E, Jung S, Voortman S, Winterhager E, Brandau S, Garbi N, Kurrer M, Eriksson U, Gunzer M*, Hasenberg M*. CD11c.DTR mice develop a fatal fulminant myocarditis after local or systemic treatment with diphtheria toxin. Eur J Immunol. 2016 Aug;46(8):2028-42. (*senior authors)

Esser D, Hoffmann L, Pham TK, Bräsen C, Qiu W, Wright PC, Albers SV, Siebers B. Protein phosphorylation and its role in archaeal signal transduction. FEMS Microbiol Rev. 2016 Sep;40(5):625-47. Review.

Hampp S, Kiessling T, Buechle K, Mansilla SF, Thomale J, Rall M, Ahn J, Pospiech H, Gottifredi V, Wiesmüller L. DNA damage tolerance pathway involving DNA polymerase ι and the tumor suppressor p53 regulates DNA replication fork progression. Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4311-9.

Crivello P, Heinold A, Rebmann V, Ottinger HD,Horn PA, Beelen DW, Fleischhauer K. Functional distance between recipient and donor HLA-DPB1 determines non-permissive mismatches in unrelated HCT. Blood. 2016 Jul 7;128(1):120-9.

von der Ecken J, Heissler SM, Pathan-Chhatbar S, Manstein DJ, Raunser S.Cryo-EM structure of a human cytoplasmic actomyosin complex at near-atomic resolution. Nature. 2016 Jun 30;534(7609):724-8.

Moses K, Klein JC, Männ L, Klingberg A, Gunzer M, Brandau S. Survival of residual neutrophils and accelerated myelopoiesis limit the efficacy of antibody-mediated depletion of Ly-6G+ cells in tumor-bearing mice. J Leukoc Biol. 2016 Jun;99(6):811-23.

Beyer M, Abdullah Z, Chemnitz JM, Maisel D, Sander J, Lehmann C, Thabet Y, Shinde PV, Schmidleithner L, Köhne M, Trebicka J, Schierwagen R, Hofmann A, Popov A, Lang KS, Oxenius A, Buch T, Kurts C, Heikenwalder M, Fätkenheuer G, Lang PA, Hartmann P, Knolle PA, Schultze JL. Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. Nat Immunol.2016 May;17(5):593-603.

Wirsdörfer F, de Leve S, Cappuccini F, Eldh T, Meyer AV, Gau E, Thompson LF, Chen NY, Karmouty-Quintana H, Fischer U, Kasper M, Klein D, Ritchey JW, Blackburn MR, Westendorf AM, Stuschke M, Jendrossek V. Extracellular adenosine production by ecto-5'-nucleotidase (CD73) enhances radiation-induced lung fibrosis. Cancer Res. 2016 May 15;76(10):3045-56.

Weissmann F, Petzold G, VanderLinden R, Huis In 't Veld PJ, Brown NG, Lampert F, Westermann S, Stark H, Schulman BA, Peters JM. biGBac enables rapid gene assembly for the expression of large multisubunit protein complexes. Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2564-9.

Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol.2016 Apr;17(4):452-63.

Friese A, Faesen AC, Huis in 't Veld PJ, Fischböck J, Prumbaum D, Petrovic A, Raunser S, Herzog F, Musacchio A. Molecular requirements for the inter-subunit interaction and kinetochore recruitment of SKAP and Astrin. Nat Commun. 2016 Apr 20;7:11407.

Borisy G, Heald R, Howard J, Janke C, Musacchio A, Nogales E. Microtubules: 50 years on from the discovery of tubulin. Nat Rev Mol Cell Biol. 2016 Apr 22;17(5):322-8.

Kaur A et.al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature 2016 Apr 14;532(7598):250-4.

Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol.2016 Apr;17(4):452-63.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016 Mar 25;351(6280):1463-9.

Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, Wang Q, Imbusch CD, Serva A, Koser SD, Brocks D, Lipka DB, Bogatyrova O, Weichenhan D, Brors B, Rassenti L, Kipps TJ, Mertens D, Zapatka M, Lichter P, Döhner H, Küppers R, Zenz T, Stilgenbauer S, Byrd JC, Plass C. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. Mar;48(3):253-64.

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G,Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-57.

Zec K, Volke J, Vijitha N, Thiebes S, Gunzer M, Kurts C, Engel DR. Neutrophil Migration into the Infected Uroepithelium Is Regulated by the Crosstalk between Resident and Helper Macrophages. Pathogens. 2016 Feb 4;5(1).

Hönes JM, Botezatu L, Helness A, Vadnais C, Vassen L, Robert F, Hergenhan SM, Thivakaran A, Schütte J, Al-Matary YS, Lams RF, Fraszscak J, Makishima H, Radivoyevitch T, Przychodzen B, da Conceição Castro SV, Görgens A, Giebel B, Klein-Hitpass L, Lennartz K, Heuser M, Thiede C, Ehninger G,Dührsen U, Maciejewski J, Möröy T, Khandanpour C. GFI1 as a novel prognostic and therapeutic factor for AML/MDS. Leukemia. 2016 Jun;30(6):1237-45.

Rolle AM, Hasenberg M*, Thornton CR, Solouk-Saran D, Männ L, Weski J, Maurer A, Fischer E, Spycher PR, Schibli R, Boschetti F, Stegemann-Koniszewski S, Bruder D, Severin GW, Autenrieth SE, Krappmann S, Davies G, Pichler BJ, Gunzer M**, Wiehr S. ImmunoPET/MR imaging allows specific detection of Aspergillus fumigatus lung infection in vivo. Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E1026-33, **corresponding senior author.

Yao JC et.al., Fourth Trial (RADIANT-4) Study Group. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar 5;387(10022):968-77.

Costa P, Lohmiller T, Trosien I, Savitsky A, Lubitz W, Fernandez-Oliva M, Sanchez-Garcia E, Sander W. Light and Temperature Control of the Spin State of Bis(p-methoxyphenyl)carbene: A Magnetically Bistable Carbene. J Am Chem Soc. 2016 Feb 10;138(5):1622-9.

Henkel S, Costa P, Klute L, Sokkar P, Fernandez-Oliva M, Thiel W, Sanchez-Garcia E, Sander W. Switching the Spin State of Diphenylcarbene via Halogen Bonding. J Am Chem Soc. 2016 Feb 10;138(5):1689-97.

Schultz BT, Teigler JE, Pissani F, Oster AF, Kranias G, Alter G, Marovich M, Eller MA, Dittmer U, Robb ML, Kim JH, Michael NL, Bolton D, Streeck H. Circulating HIV-Specific Interleukin-21+CD4+ T Cells Represent Peripheral Tfh Cells with Antigen-Dependent Helper Functions. Immunity 2016 Jan 19;44(1):167-78.

Li M, Ehlers M, Schlesiger S, Zellermann E, Knauer SK, Schmuck C. Incorporation of a Non-Natural Arginine Analogue into a Cyclic Peptide Leads to Formation of Positively Charged Nanofibers Capable of Gene Transfection. Angew Chem Int Ed Engl. 2016 Jan 11;55(2):598-601.

↑2016 top


More publications